Genomic Health (GHDX) Misses Q2 EPS by 2c

Genomic Health (NASDAQ: GHDX) reported Q2 EPS of ($0.29), $0.02 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $70.6 million versus the consensus estimate of $71.65 million.

"In the second quarter we successfully executed on our key growth drivers, including Oncotype DX® test growth driven by DCIS, prostate cancer and international, all of which reached record levels," said Kim Popovits, Chairman of the Board, Chief Executive Officer and President of Genomic Health. "With this momentum, anticipated Medicare revenue for our prostate cancer test in the fourth quarter and continued reimbursement success across markets and geographies, we believe we are well positioned to deliver profitability and double-digit revenue growth by the end of the year."

For earnings history and earnings-related data on Genomic Health (GHDX) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• LeonaBio, Inc. (LONA) Tops Q2 EPS by 32c
• Phillip Securities Reiterates Buy Rating on Sea Ltd. (SE)